Oxycodon-Hcl/Naloxon-Hcl Al (Naloxone, Oxycodone)

Naloxone, the active ingredient in Oxycodon-Hcl/Naloxon-Hcl Al, is a combination opioid analgesic and opioid antagonist presented as a solid dosage form for oral use. It is used to manage moderate to severe pain while reducing the risk of opioid‑induced constipation and respiratory depression in adult patients. GNH USA supplies Oxycodon-Hcl/Naloxon-Hcl Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oxycodon-Hcl/Naloxon-Hcl Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Naloxone/Oxycodone is a combination product that provides analgesia while mitigating opioid‑related side effects.

- Acute postoperative pain: delivers effective pain relief while reducing opioid‑induced respiratory depression. - Cancer‑related chronic pain: provides sustained analgesia for patients with breakthrough pain. - Severe traumatic injury pain: offers rapid onset of strong analgesia with a built‑in safety mechanism. - Opioid rotation or tapering: assists in transitioning patients to lower‑dose opioid regimens with reduced risk of withdrawal. - Palliative care: supports comfort management in end‑of‑life settings where high‑potency analgesia is required.

Side effects are reported across a range of frequencies and severities.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel motility. - Dizziness: transient light‑headedness. - Sedation: feeling of sleepiness. - Dry mouth: reduced salivation. - Headache: mild cranial discomfort.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing, especially with high doses. - Severe hypotension: marked drop in blood pressure. - Hepatotoxicity: liver enzyme elevations. - Allergic reactions: rash, itching, or swelling. - Seizures: rare convulsive episodes. - Opioid dependence: risk of misuse with prolonged therapy.

When prescribing Oxycodon-Hcl/Naloxon-Hcl Al, clinicians should consider several safety measures.

- Assess pain severity: ensure the combination is appropriate for the intensity of pain. - Review opioid history: evaluate prior opioid exposure and tolerance. - Monitor for respiratory depression: especially during initiation or dose changes. - Caution in hepatic impairment: adjust use if liver function is compromised. - Avoid in patients with known hypersensitivity to either component. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Oxycodon-Hcl/Naloxon-Hcl Al may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Benzodiazepines: additive central nervous system depression can increase risk of respiratory compromise. - MAO inhibitors: may precipitate severe hypertension or serotonin syndrome. - CNS depressants: combined effect may lead to profound sedation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise oxycodone plasma levels. - CYP3A4 inducers (e.g., rifampicin): may reduce analgesic efficacy. - Anticholinergic agents: can exacerbate constipation. - Diuretics: may enhance hypotensive effects. - Serotonergic drugs: potential for serotonin syndrome, especially with high opioid doses.